Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not true
No you are wrong again
You make your money from inactivity.
Be patient
No they are not
Oxis cured the cancer for a lady :)
Once it hits the Nasdaq it will sky rocket as that's when the institutional investors will pour their money in as they are not allowed on the OTC.
Seize the opportunity quickly!
Results out in June 2017 :)
It will be just fine :) Oxis cured a ladies cancer :)
Oxis Announces Treatment of First Patient in FDA Phase 2 Trial of Cancer Drug OXS-1550
http://finance.yahoo.com/news/oxis-international-inc-announces-treatment-134500726.html
No it is way undervalued :)
BUY BUY BUY
Oxis cured a ladies cancer :)
That is BIG!
Oxis International Inc. Announces Approval of FDA Phase 2 Trial with Its Bispecific Antibody OXS-1550
LOS ANGELES, CA / ACCESSWIRE / April 4, 2017 / Oxis International Inc. (OTCQB:OXIS and Euronext Paris OXI.PA) announced today that the Food and Drug Administration has cleared the way for the Company's wholly owned subsidiary, Oxis Biotech Inc., to begin a FDA Phase 2 clinical trial for its promising cancer treatment OXS-1550 in the treatment of lymphoma and leukemia.
Oxis Biotech, a targeted immuno-oncology company focused on novel antibody constructs, owns the worldwide rights to commercialize OXS-1550.
The FDA Phase 2 clinical trial will be conducted with Oxis' partner, the University of Minnesota's Masonic Cancer Center. Researchers at the University of Minnesota recently completed a FDA Phase 1 trial of OXS-1550. The Phase 1 portion of the trial completed a safety review to determine the safe and effective dose of the drug.
OXS-1550 uses a proprietary immunoconjugate platform technology, as a treatment for leukemia and other blood-born cancers. What sets OXS-1550 (DT2219ARL) apart from other treatments, such as chemotherapy, is that it is designed to specifically target and kill cancer cells minimizing damage to normal tissues.
"This milestone represents a major step forward for our technology. The product has performed well in its phase 1 studies in blood cancers and we look forward to positive results in Phase 2," said Anthony Cataldo, Chairman and Chief Executive Officer of Oxis. "This next generation drug has the possibility of treating a number of different liquid tumors and, if successful, will drastically change the paradigm now being developed that relies on highly expensive autologous cell therapies such as presented by Kite Pharma, Inc. (KITE), Juno Therapeutics, Inc. (JUNO) and other autologous or semi-autologous and adoptive therapy approaches currently under development."
Dr. Daniel Vallera, director of the section on Molecular Cancer Therapeutics at the University of Minnesota Cancer Center, lead developer of OXS-1550 said, "The FDA's clearance for Phase 2 is an important step forward for this cancer treatment."
Dr. Vallera has spent 35 years with the University of Minnesota's cancer center, where he oversees a laboratory specializing in the development of biological recombinant drugs focusing on bispecific antibody therapies that directly deliver toxic signals to cancer cells.
"We are excited to see this new therapy proceed to Phase 2," Dr. Vallera said. "So many of these patients presenting with chemotherapy refractory cancer have few, if any, alternative choices for cancer treatment."
About Oxis Biotech, Inc.: Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
Forward-Looking Statements: Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
http://finance.yahoo.com/news/oxis-international-inc-announces-approval-123000457.html
What do you mean?
Make sure you watch the facts in this video interview
Oxis Biotech featured on Worldwide Business with kathy ireland®
HERE ARE THE FACTS
VIDEO INTERVIEW OF ALL THE FACTS
the company announced that the Food and Drug Administration cleared the way for OXIS’ subsidiary company, Oxis Biotech, for a clinical trial.
Now, if you have not heard of OXIS International Inc or Oxis biotech, it develops and commercializes immunotherapeutics for the treatment of cancer. The company’s lead drug candidate, OXS-1550 is a novel bispecific scFv recombinant fusion protein-drug conjugate, which is composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. In other words, the company’s lead drug candidate targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
Getting back to the company news. OXIS International, Inc. (OTCMKTS:OXIS) recently announced Oxis Biotech received FDA approval for a Phase II clinical trial for its cancer treatment OXS-1550, targeting lymphoma and leukemia. Now, the company also recently entered into a sponsored research agreement with the University of Minnesota in order to conduct a toxicity study of its TriKE cancer treatment (OXS-3550), which is a required step before researchers can apply for a Phase 1 clinical trial with the Food and Drug Administration.
That in mind, the FDA Phase II clinical trial of OXS-1550 will be conducted with its partner, the University of Minnesota’s Masonic Cancer Center. The company recently completed an FDA Phase I trial of OXS-1550 at the center
According to Anthony Cataldo, Chairman and Chief Executive Officer of Oxis, “This milestone represents a major step forward for our technology. The product has performed well in its phase 1 studies in blood cancers and we look forward to positive results in Phase 2.”
Cataldo added, “This next generation drug has the possibility of treating a number of different liquid tumors and, if successful, will drastically change the paradigm now being developed that relies on highly expensive autologous cell therapies such as presented by Kite Pharma, Inc. (KITE), Juno Therapeutics, Inc. (JUNO) and other autologous or semi-autologous and adoptive therapy approaches currently under development.”
Dr. Daniel Vallera, director of the section on Molecular Cancer Therapeutics at the University of Minnesota Cancer Center, lead developer of OXS-1550 stated, “The FDA’s clearance for Phase 2 is an important step forward for this cancer treatment.”
Dr. Vallera has spent 35 years with the University of Minnesota’s cancer center, where he oversees a laboratory specializing in the development of biological recombinant drugs focusing on bispecific antibody therapies that directly deliver toxic signals to cancer cells.
“We are excited to see this new therapy proceed to Phase 2,” Dr. Vallera said. “So many of these patients presenting with chemotherapy refractory cancer have few, if any, alternative choices for cancer treatment.”
In addition to this news, Oxis Biotech recently announced the bispecific cancer immunotherapy approach, the premise that its leading drug is based on, was lauded as a promising alternative to expensive CAR-T therapy.
Cataldo stated, “This clearly demonstrates that the bispecific approach we’re taking with OXS-1550 is a positive alternative to CAR-T cell therapy solutions…It’s effective. It’s cost-effective. It’s non-invasive. It’s saves lives and it’s associated with fewer adverse effects.”
Oxis International Enters into a Sponsored Research Agreement with the University of Minnesota
LOS ANGELES, CA / ACCESSWIRE / March 23, 2017 / Oxis International Inc. (OTCQB:OXIS and Euronext Paris OXI.PA) announced today that it has entered into a sponsored research agreement with the University of Minnesota to conduct a toxicity study of its TriKE cancer treatment (OXS-3550), a required step before researchers can apply for a Phase 1 clinical trial with the Food and Drug Administration.
Under the agreement, Oxis will pay for the university to conduct a study that will determine the optimal dose for OXS-3550. The research will be led by Dr. Daniel Vallera, Director of the section on Molecular Cancer Therapeutics at the University of Minnesota Masonic Cancer Center. He is a member of the Scientific Advisory Board of Oxis' wholly owned subsidiary, Oxis Biotech Inc.
Oxis and the University of Minnesota have reached a licensing agreement under which Oxis holds the worldwide rights to commercialize the TriKE therapy, once it receives regulatory approval.
"The agreement will support the TriKE toxicology studies that are needed for an FDA submission, which we expect to file soon," said Dr. Jeffrey Miller, Deputy Director of the University of Minnesota Masonic Cancer Center. "We are excited to see this drug development move forward."
Dr. Vallera and Dr. Miller were instrumental in developing Trispecific Killer Engager (TriKE) cancer therapy and Bispecific Killer Engager (BiKE). Both platforms have been licensed by Oxis. The BiKE therapy, OXS-1550, is currently in an FDA Phase 1/Phase 2 clinical trial in Minnesota.
Both treatments empower the body's immune system to identify and selectively kill cancer cells, while leaving healthy cells alone.
Dr. Vallera has spent 35 years with the University of Minnesota's cancer center, where he oversees a laboratory specializing in the development of biological recombinant drugs focusing on bispecific antibody therapies that directly deliver toxic signals to cancer cells.
About Oxis Biotech, Inc.: Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-2175 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
Forward-Looking Statements: Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
http://finance.yahoo.com/news/oxis-international-enters-sponsored-research-120000879.html
Oxis Continues Push For Zika Cure, Following New Confirmed Case In South Korea
Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. [OTC: OXIS and Euronext Paris: OXI.PA], announced today that it is continuing to focus on a cure for the Zika virus, as the mosquito-transmitted disease spreads globally.
South Korea reported its first confirmed case of the Zika virus on March 22. Health officials from that country said a 43-year-old tested positive for the disease after returning to the country from a trip to Brazil.
On March 1, Oxis disclosed that Dr. Sean Xie, a research scientist, professor of pharmacology at the University of Pittsburgh and a member of Oxis' Scientific Advisory Board, has identified small molecule chemical inhibitors that target nonstructural proteins "with the potential for blocking Zika virus replication."
Dr. Xie is leading a Zika research project with Oxis. He said he used his TargetHunter computer modeling system to break down key proteins the Zika virus needs for replication. That allowed him to identify inhibitors that could block the virus from replicating.
Oxis is hopeful that Dr. Xie's findings could help develop a vaccine and treatment for the Zika virus and greatly slow the spread of the disease.
"With a new confirmed case in South Korea, Oxis' efforts to find a realistic solution to the Zika problem remains a key focus for our company," said Oxis Chairman and Chief Executive Anthony Cataldo. "The progress that Dr. Xie has already made has us on the path to creating a realistic solution to stop the spread of Zika and treat those already infected with the disease."
There is growing evidence of a link between Zika and microcephaly in babies, according to news reports. The condition is defined by unusually small heads that can result in developmental problems.
Brazil said it has confirmed more than 860 cases of microcephaly, and believes many of them might be related to Zika infections of the mothers. The country is also investigating more than 4,200 additional suspected cases of the birth defect.
The Zika virus, first identified 50 years ago, is spread through mosquito bites and has been linked to an increase in a rare birth defect, making the virus a significant threat to pregnant women. Additionally, there is a concern that the Zika virus can be spread sexually.
In January, the World Health Organization designated the Zika virus an international public health emergency. The agency estimated that virus will spread throughout the world and infect some 4 million people by the end of the year.
The U.S. Centers for Disease Control on February 26, 2016, advised pregnant women to avoid traveling to Brazil, site of the upcoming Olympic Games, because the Zika virus is a particular problem in that country. As many as 1.5 million people are believed to have become infected with Zika in Brazil.
Zika is just one focus for Oxis. The company is in collaboration with top research scientists to use immunotherapy to treat cancer and other diseases. Its lead drug candidate, OXS-1550, is currently in Phase 1/Phase 2 clinical trial at the University of Minnesota Masonic Cancer Center as a treatment for non-Hodgkins lymphoma and leukemia.
Inventors of OXS-1550 recently received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550.
ABOUT OXIS INTERNATIONAL, INC. - Oxis International, Inc., through a wholly owned subsidiary, Oxis Biotech, Inc., develops innovative drugs focused on the treatment of cancer and other unmet medical needs. Oxis' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 simultaneously targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
FORWARD LOOKING STATEMENTS - Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
The value is going up the price is on SALE :)
Best time to buy :)
OXIS Could Hold The Key To Curing Cancer
An aging population, a larger amount of the healthcare spending going toward drugs and treatments (roughly 10% of overall healthcare spending) and new technologies being used to create new and more effective compounds (the FDA approved the second most drugs ever in 2015) are all key factors to stronger future growth potential for biotechnology. Let’s also not forget the rise in global viral threats like the Zika virus, which has recently come to light.
So why bring all of this up? Many biotech companies are undertaking phase trials, have projects under development, and some have just begun to start capitalizing their action plans; meaning, biotechnology is usually a longer road ahead. The allure of underfollowed companies has been a big focus as of late with the mergers and acquisitions climate becoming red hot.
With eyes everywhere, the Pfizers and Johnson & Johnsons of the world are targeting smaller companies during a time when the mergers and acquisitions climate is red hot. In fact an analyst from Zack’s Research has stated, “…Encouraging industry trends including a merger & acquisition frenzy, promising drug launches, cost-cutting efforts, an aging population, ever-increasing demand for new drugs, higher healthcare spending, expansion into emerging markets and Obamacare will continue to fuel growth in the sector.”
So where can investors look to gain ground without breaking the bank on a higher priced stock? In my opinion, small and micro-caps. But unlike many that are just “developing an idea” or “planning for pre-phase trials”, there has been one company with proven management which has begun to catch real attention for their very real therapy for cancer, among other things within their pipeline.
OXIS International, Inc. (OTCMKTS:OXIS) could be one of the most undervalued biotechnology stocks on the market today and I’ll explain why I think this. This company through its wholly owned subsidiary, Oxis Biotech, Inc. develops and commercializes innovative immunotherapeutics for the treatment of cancer. And it’s the company’s lead drug that has captivated the attention of biotech investors.
OXIS has a robust portfolio of next-generation cancer initiatives and its lead drug candidate, OXS-1550, is in Phase 1/Phase 2 clinical trials at the University of Minnesota Masonic Cancer Center as a treatment for non-Hodgkins lymphoma and leukemia.
OXIS Holds Worldwide Exclusive Rights & U.S. Patent For Lead Therapy
Oxis International holds worldwide exclusive rights to develop and commercialize OXS-1550. Furthermore, inventors of the therapy recently received a Notice of Allowance from the United States Patent and Trademark Office. U.S. Patent No. 9,371,386 provides bi-specific targeting compositions including a cytotoxic agent conjugated to a targeting moiety and a binding fragment which targets CD19 or CD22. The patent also includes methods of treating humans having lymphoma or B-cell malignancies using the patented composition.
OXIS further has licensed exclusive rights to three Antibody-drug conjugates (ADCs) through an agreement made in early 2015 with MultiCell Immunotherapeutics, Inc. MultiCell will prepare these ADCs for further evaluation as prospective therapeutics for the treatment of triple-negative breast cancer, as well as multiple myeloma and associated osteolytic bone disease.
OXS-1550 Demonstrates Success In Early Human Clinical Trials
What should beg immediate attention on OXIS is that OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. The company’s FDA-approved clinical trial is currently being conducted under the watch of Dr. Daniel Vallera, a research scientist who developed the drug and is actually a member of the Scientific Advisory Board of Oxis Biotech.
In a recent announcement, OXIS added six new patients to its Phase 1/ Phase 2 Clinical trials. This brought the total number to 32 patients currently participating in the trial.
OXS-1550 Proven To Initiate Complete Remission In Early Trials
Unlike many other drug therapy companies, OXIS…this tiny biotech…has actually realized an occurance of complete remission during its Phase 1/Phase 2 trials. In an unprecedented instance, the company states that one of its patients who was given an approved increased dosage of OXS-1550 saw complete remission in her (Cynthia Cattell) lymphoma.
This is something that not even much larger and much more capitalized drug thereapy companies can boast in Phase 3 let alone Phase 1/ Phase 2. According to OXIS press releases, Cattell stated that all “other aggressive B-cell lymphoma treatments” had failed until she was treated with OXS-1550.
The cure for cancer? These results certainly reinforce the stance on OXIS from a drug perspective.
Search & Destroy
What sets OXS-1550 apart from other drug therapies is the it is designed to search out cancer cells and destroy them completely. This is all while having no adverse affects on healthy cells.
“This drug is a powerful alternative to chemotherapy since many patients fail chemotherapy or reach the toxic limits of their chemotherapy. It is urgently needed in the clinic.”
-Dr. Daniel Vallera.
Strong Pipeline Of Other Therapies
Outside of the lead candidate OXS-1550, Oxis has several other key drug candidates that address growing needs within high profile segments:
OXS-4235
Addresses a type of cancer called Multiple myeloma, which forms in white blood cells and affects nearly 30,000 people in the US per year. About 1/3 of those affected end up dying. Due to the serious nature of this bone marrow cancer, multiple myeloma can actually cause bone lesions, and even produce abnormal proteins that can accumulate in urine. OXS-4235 was designed as a chemical compound to inhibit osteoclastic bone destruction in multiple myeloma.
OXS-2175
Addresses triple negative breast cancer. According to the American Cancer Society there were over a quarter million new cases of invasive breast cancer in the US last year with over 40,000 deaths coming from breast cancer during that period. OXS-2175 is a small molecule therapeutic candidate that has shown “promise,” according to the company, in early stage preclinical in vitro and in vivo models of triple negative breast cancer. Due to the fact that there is no known or pending drug therapy for the treatment of Triple Negative breast Cancer, this opens another opportunity for Oxis International to capitalize on.
Industry Opportunity
Multiple Myeloma Presenting Multi Billion Dollar Opportunity
According to FiercePharma, Celgene’s cancer drug Revlimid® for the treatment of multiple myeloma generated nearly $5 billion in revenue for the company in 2014. Analysts believe sales of Revlimid could double within 5 years as a result of FDA’s recent approval of expanded labeling concerning the use of Revlimid in combination with dexamethasone for patients newly diagnosed with multiple myeloma. About 93,600 patients are living with multiple myeloma in Europe and about 88,499 patients are living with it in the United States, Celgene said.
Limited Breast Cancer Treatments Roll Out The Carpet For New Therapies…
PDL BioPharma, Inc. stated its licensee Genentech, Inc. reported sales of Herceptin® which is used to treat HER2 breast cancer totaled $7.3 billion in 2014. Of the 280,000 patients in the USA diagnosed annually with breast cancer, about 20% are diagnosed with triple-negative breast cancer.
Treatment options for triple-negative breast cancer patients are limited because the three most common types of receptors known to fuel most breast cancer growth – estrogen, progesterone, and the HER-2/neu gene – are not present in the triple-negative breast cancer cells, hence patients are ineligible for treatment with either hormonal or HER2-targeted agents such as Herceptin. Treatment typically involves non-targeted cytotoxic chemotherapies.
Proven Management
Obviously no company can expect to “go the distance” without a sound leadership team at the helm and OXIS has just that. As CEO, Anthony Cataldo is no stranger to emerging biotech and has been credited with taking companies “to the next level”. In fact Mr. Cataldo served as Founder and Chairman/CEO of Genesis Biopharma, Inc., now known as Lion Biotechnologies, Inc.(LBIO).
Mr. Cataldo created the highly successful Lion/Genesis (LBIO) with the inclusion of assets acquired from the National Cancer Institute for the treatment of stage four melanoma. Cataldo managed to grow LBIO’s market-cap 250x through a simple process: acquiring strong IP, having a strong research team, and attracting the right group of inside ownership to build a REAL biotechnology enterprise.
Mr. Cataldo has extensive experience in the biotechnology sector having served as Chairman/CEO of several biotech companies including: MultiCell Technologies, Inc., Calypte Biomedical Corporation, and Senetek, PLC.
At the end of the day, penny stocks of any kind can be risky and biotechnology investments as a whole can have their own risk involved. Many cannot complete phase trials simply due to lack of funding and others wind up going to Phase 3 and finding futility due to lack of recordable or efficacious results.
Oxis, on the other hand, has already proven that its lead candidate, OXS-1550 has shown real promise. How? For starters, in its current trial phases, one patient has already been in a year of remission following the approved increased dosage of OXS-1550. In addition to that the company is also in active development and preclinical trials of two therapies that address very specific and very unmet diseases. This mix of market exclusivity and future pipeline would be expected from much larger companies but Oxis only has a market cap of roughly $6.5million and trades under $0.50.
So just as I said above, where can investors look to gain ground without breaking the bank on a higher priced stock? I feel as though Oxis International has been one company with proven management, which has begun to catch real attention for their very real therapy through its lead drug OXS-1550 and will be something to watch closely.
https://www.smarteranalyst.com/2016/07/13/one-small-biotech-stock-hold-key-curing-cancer/
Oxis Biotech Gains Key Patent Ruling For Its Cancer Drug, OXS-1550
OS ANGELES, Feb. 23, 2016 /PRNewswire/ -- Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. [OTC: OXIS and Euronext Paris: OXI.PA] announced today that inventors of OXS-1550 received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550, a novel therapy for the treatment of various human cancers.
"We are pleased the USPTO has agreed that OXS-1550 is a patentable therapeutic composition. This is a significant milestone for Oxis and will attribute meaningful value to our existing IP portfolio," said Anthony J. Cataldo, Chairman and Chief Executive Officer of Oxis Biotech.
Dr. Daniel Vallera, the inventor of OXS-1550 and Director of the Section on Molecular Cancer Therapeutics at the University of Minnesota Masonic Cancer Center, said he believes OXS-1550 will play an important role in the treatment of cancer. The drug is designed to identify certain cancer cells and kill them, without damaging healthy cells.
"We believe OXS-1550 to be a powerful alternative to existing chemotherapies, since many patients fail chemotherapy or reach the toxic limits of their therapy," Vallera said.
The patent decision comes as OXS-1550 is being evaluated in a new Phase 1/Phase 2 clinical trial. The objective of the Phase 1 study is to identify the Maximum Tolerated Dose (MTD), and the optimized dose and regimen to be used in the Phase 2 study.
Enrollment of patients into the Phase 2 study will begin after the Phase 1 study is completed. The Phase 2 study is a two-stage, two-ARM design. Patients from the Phase 1 study plus an additional 9 patients will be enrolled in stage 1 of the Phase 2 study. If one patient enrolled in the Phase 2, stage 1 part of the study has a positive response, then an additional 8 patients will be enrolled in the Phase 2 stage of the study. At a maximum, up to 29 patients will be enrolled across both the Phase 1 and Phase 2 (stages 1 & 2) studies.
OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. CD19 is a membrane glycoprotein present on the surface of all stages of B lymphocyte development, and is also expressed on most B-cell mature lymphoma cells and leukemia cells. CD22 is a glycoprotein expressed on B-lineage lymphoid precursors, including precursor B acute lymphoblastic leukemia, and often is co-expressed with CD19 on mature B-cell malignancies.
OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.
In an earlier Phase 1 clinical trial, twenty-five patients with mature or precursor B-cell lymphoid malignancies expressing CD19 and/or CD22 were enrolled. When the study allowed for an increase in the dose level (60 mg/kg) in the final 9 patients, durable objective responses occurred in 2 patients; one patient continues to be in complete remission after being administered 2 cycles of OXS-1550. For further information about the earlier Phase 1 clinical trial, see Bachanova, V., et. al., Clin Cancer Res; 21(6) March 15, 2015.
About Oxis Biotech, Inc.: Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-2175 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
Forward-Looking Statements: Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
http://www.prnewswire.com/news-releases/oxis-biotech-gains-key-patent-ruling-for-its-cancer-drug-oxs-1550-300224326.html
Oxis Biotech Announces U.S. Patent and Trademark Office Notification of Patent Issuance for Oxis-4235 as Treatment for Multiple Myeloma
Oxis International, Inc. (OXIS) (OXIS.PA) parent company of Oxis Biotech, focused on the development and commercialization of immunotherapy for the treatment of cancer, announced today it received notification from the U.S. Patent and Trademark Office a patent will be issued on February 28, 2017 for its drug candidate OXIS-4235 for the treatment of myeloma.
The patent clears the way for Oxis Biotech to begin the process of pursuing clinical trials for the new drug.
The drug is a P62-ZZ chemical inhibitor intended for use as a treatment for multiple myeloma. According to the American Cancer Society, more than 30,000 people are expected to be diagnosed with the disease this year and more than 12,000 are expected to die from it.
Dr. Sean Xie of Pittsburgh, Pa., developed the drug. The drug is intended to stop the growth of multiple myeloma cells without harming healthy cells. In addition to shrinking the tumors, the dual purpose drug is also intended to increase bone density, a second benefit of the technology.
Oxis Biotech, through its licensing agreement with Dr. Xie, holds the exclusive worldwide rights to commercialize this technology.
"Bone density shrinkage is one of the biggest problems of multiple myeloma. Bones wither away. This dual action drug is extremely promising," said Oxis CEO Anthony Cataldo. "We have always had great confidence in Dr. Xie's work related to multiple myeloma. The issuance of this patent points out the unique and novel technology Dr. Xie has developed. We are incredibly happy to add it to our pipeline."
The USPTO indicated it will issue Patent No. 9,580,382 for the technology on February 28, 2017.
About Oxis Biotech, Inc.: Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-2175 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
Forward-Looking Statements: Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
http://finance.yahoo.com/news/oxis-biotech-announces-u-patent-131500785.html
This stock is undervalued everyone knows this.
Oxis cured cancer for the 1 patient who was allowed to receive the optimal high dose twice she was then cured :)
Smart move! :) Oxis will sky rocket.
They cured cancer for the 1 patient who was allowed to be given the optimal dose twice :)
Oxis Announces Treatment of First Patient in FDA Phase 2 Trial of Cancer Drug OXS-1550
http://finance.yahoo.com/news/oxis-international-inc-announces-treatment-134500726.html
Oxis International Inc. (OTCQB:OXIS and Euronext Paris OXI.PA) announced today that the first patient has begun treatment in a Food and Drug Administration-approved Phase 2 clinical trial of its promising cancer therapy, OXS-1550.
Oxis Biotech, a wholly owned subsidiary of Oxis International, owns the worldwide rights to commercialize OXS-1550. The targeted immuno-oncology company is focused on novel antibody constructs that provide alternative treatments to cancer patients for whom existing therapies have failed.
The Phase 2 clinical trial is being conducted with Oxis' partner, the University of Minnesota's Masonic Cancer Center. Researchers at the University of Minnesota recently completed a Phase 1 trial of OXS-1550. The Phase 1 portion of the trial involved a safety review to determine the safe and effective dose of the drug.
Anthony Cataldo, Chairman and Chief Executive Officer of Oxis, said the initiation of Phase 2 patient treatment is a key step for the company and a milestone for the promising technology.
"The initiation of Phase 2 patient treatment of OXS-1550 brings us one step closer in our company's effort to provide a promising alternative to existing technology," Mr. Cataldo said. "The product performed well in Phase 1 studies of blood cancers and we look forward to providing a targeted immunotherapy product that has the capability of treating a number of different liquid tumors." OXS-1550 is an ADC (Antibody Drug Conjugate) drug. ADCs, such as ADCETRIS® (brentuximab vedotin) from Seattle Genetics (SGEN), a first-in-class FDA approved antibody-drug conjugate, have paved the way for this type of next generation platform drug.
OXS-1550 uses a proprietary immunoconjugate platform technology as a treatment for leukemia and other blood-born cancers. What sets OXS-1550 (DT2219ARL) apart from other treatments, such as chemotherapy, is that it is designed to specifically target and kill cancer cells while minimizing damage to normal tissues.
Dr. Daniel Vallera, director of the section on Molecular Cancer Therapeutics at the University of Minnesota Cancer Center, helped develop OXS-1550. He said, "The initiation of Phase 2 patient treatment is a key opportunity to demonstrate the effectiveness of this promising cancer therapy. This brings us one step closer to an important alternative to invasive chemotherapies and costly cell therapies, Kite Pharma, Inc. (KITE), Juno Juno Therapeutics (JUNO), for cancer patients."
The news about OXS-1550 follows other good news about cancer treatments in the Oxis pipeline.
Additionally, on March 23, Oxis announced that it entered into a sponsored research agreement with the University of Minnesota to conduct a toxicity study of its TriKE cancer treatment (OXS-3550), a required step before researchers can apply for a Phase 1 clinical trial with the FDA.
Under the TriKe agreement, Oxis will pay for the university to conduct a study that will determine the optimal dose for OXS-3550.
About Oxis Biotech, Inc.:
Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. OXS-2175 is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
Forward-Looking Statements:
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
I only buy more when it is undervalued :)
I own a great company which is undervalued :)
Yes oxis is undervalued everyone knows this.
Oxis cured cancer for that lady as soon as the FDA allowed Oxis to give 2 optimal high doses to 1 patient.
That's worth more than 30 billion to me :)
No better to wait. We will get an EVEN bigger valuation buy out after the June 2017 results :)
Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. [OTC: OXIS and Euronext Paris: OXI.PA] announced today that inventors of OXS-1550 received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550, a novel therapy for the treatment of various human cancers.
"We are pleased the USPTO has agreed that OXS-1550 is a patentable therapeutic composition. This is a significant milestone for Oxis and will attribute meaningful value to our existing IP portfolio," said Anthony J. Cataldo, Chairman and Chief Executive Officer of Oxis Biotech.
Dr. Daniel Vallera, the inventor of OXS-1550 and Director of the Section on Molecular Cancer Therapeutics at the University of Minnesota Masonic Cancer Center, said he believes OXS-1550 will play an important role in the treatment of cancer. The drug is designed to identify certain cancer cells and kill them, without damaging healthy cells.
"We believe OXS-1550 to be a powerful alternative to existing chemotherapies, since many patients fail chemotherapy or reach the toxic limits of their therapy," Vallera said.
The patent decision comes as OXS-1550 is being evaluated in a new Phase 1/Phase 2 clinical trial. The objective of the Phase 1 study is to identify the Maximum Tolerated Dose (MTD), and the optimized dose and regimen to be used in the Phase 2 study.
Enrollment of patients into the Phase 2 study will begin after the Phase 1 study is completed. The Phase 2 study is a two-stage, two-ARM design. Patients from the Phase 1 study plus an additional 9 patients will be enrolled in stage 1 of the Phase 2 study. If one patient enrolled in the Phase 2, stage 1 part of the study has a positive response, then an additional 8 patients will be enrolled in the Phase 2 stage of the study. At a maximum, up to 29 patients will be enrolled across both the Phase 1 and Phase 2 (stages 1 & 2) studies.
OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. CD19 is a membrane glycoprotein present on the surface of all stages of B lymphocyte development, and is also expressed on most B-cell mature lymphoma cells and leukemia cells. CD22 is a glycoprotein expressed on B-lineage lymphoid precursors, including precursor B acute lymphoblastic leukemia, and often is co-expressed with CD19 on mature B-cell malignancies.
OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.
In an earlier Phase 1 clinical trial, twenty-five patients with mature or precursor B-cell lymphoid malignancies expressing CD19 and/or CD22 were enrolled. When the study allowed for an increase in the dose level (60 mg/kg) in the final 9 patients, durable objective responses occurred in 2 patients; one patient continues to be in complete remission after being administered 2 cycles of OXS-1550. For further information about the earlier Phase 1 clinical trial, see Bachanova, V., et. al., Clin Cancer Res; 21(6) March 15, 2015.
About Oxis Biotech, Inc.: Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-2175 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
Forward-Looking Statements: Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
To prevent a anti takeover
Oxis Biotech Gains Key Patent Ruling For Its Cancer Drug, OXS-1550
Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. [OTC: OXIS and Euronext Paris: OXI.PA] announced today that inventors of OXS-1550 received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550, a novel therapy for the treatment of various human cancers.
"We are pleased the USPTO has agreed that OXS-1550 is a patentable therapeutic composition. This is a significant milestone for Oxis and will attribute meaningful value to our existing IP portfolio," said Anthony J. Cataldo, Chairman and Chief Executive Officer of Oxis Biotech.
Dr. Daniel Vallera, the inventor of OXS-1550 and Director of the Section on Molecular Cancer Therapeutics at the University of Minnesota Masonic Cancer Center, said he believes OXS-1550 will play an important role in the treatment of cancer. The drug is designed to identify certain cancer cells and kill them, without damaging healthy cells.
"We believe OXS-1550 to be a powerful alternative to existing chemotherapies, since many patients fail chemotherapy or reach the toxic limits of their therapy," Vallera said.
The patent decision comes as OXS-1550 is being evaluated in a new Phase 1/Phase 2 clinical trial. The objective of the Phase 1 study is to identify the Maximum Tolerated Dose (MTD), and the optimized dose and regimen to be used in the Phase 2 study.
Enrollment of patients into the Phase 2 study will begin after the Phase 1 study is completed. The Phase 2 study is a two-stage, two-ARM design. Patients from the Phase 1 study plus an additional 9 patients will be enrolled in stage 1 of the Phase 2 study. If one patient enrolled in the Phase 2, stage 1 part of the study has a positive response, then an additional 8 patients will be enrolled in the Phase 2 stage of the study. At a maximum, up to 29 patients will be enrolled across both the Phase 1 and Phase 2 (stages 1 & 2) studies.
OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. CD19 is a membrane glycoprotein present on the surface of all stages of B lymphocyte development, and is also expressed on most B-cell mature lymphoma cells and leukemia cells. CD22 is a glycoprotein expressed on B-lineage lymphoid precursors, including precursor B acute lymphoblastic leukemia, and often is co-expressed with CD19 on mature B-cell malignancies.
OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.
In an earlier Phase 1 clinical trial, twenty-five patients with mature or precursor B-cell lymphoid malignancies expressing CD19 and/or CD22 were enrolled. When the study allowed for an increase in the dose level (60 mg/kg) in the final 9 patients, durable objective responses occurred in 2 patients; one patient continues to be in complete remission after being administered 2 cycles of OXS-1550. For further information about the earlier Phase 1 clinical trial, see Bachanova, V., et. al., Clin Cancer Res; 21(6) March 15, 2015.
About Oxis Biotech, Inc.: Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-2175 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
Forward-Looking Statements: Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Oxis is massively undervalued :) I am a value investor, it is clear you don't get it. The price is what you pay for it, the value is what you get. :)
The assets are worth easily between 3 to 30 billion
Oxis is undervalued simple! Seize the opportunity quickly :)
Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550, a novel therapy for the treatment of various human cancers.
Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. [OTC: OXIS and Euronext Paris: OXI.PA] announced today that inventors of OXS-1550 received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550, a novel therapy for the treatment of various human cancers.
"We are pleased the USPTO has agreed that OXS-1550 is a patentable therapeutic composition. This is a significant milestone for Oxis and will attribute meaningful value to our existing IP portfolio," said Anthony J. Cataldo, Chairman and Chief Executive Officer of Oxis Biotech.
Dr. Daniel Vallera, the inventor of OXS-1550 and Director of the Section on Molecular Cancer Therapeutics at the University of Minnesota Masonic Cancer Center, said he believes OXS-1550 will play an important role in the treatment of cancer. The drug is designed to identify certain cancer cells and kill them, without damaging healthy cells.
"We believe OXS-1550 to be a powerful alternative to existing chemotherapies, since many patients fail chemotherapy or reach the toxic limits of their therapy," Vallera said.
The patent decision comes as OXS-1550 is being evaluated in a new Phase 1/Phase 2 clinical trial. The objective of the Phase 1 study is to identify the Maximum Tolerated Dose (MTD), and the optimized dose and regimen to be used in the Phase 2 study.
Enrollment of patients into the Phase 2 study will begin after the Phase 1 study is completed. The Phase 2 study is a two-stage, two-ARM design. Patients from the Phase 1 study plus an additional 9 patients will be enrolled in stage 1 of the Phase 2 study. If one patient enrolled in the Phase 2, stage 1 part of the study has a positive response, then an additional 8 patients will be enrolled in the Phase 2 stage of the study. At a maximum, up to 29 patients will be enrolled across both the Phase 1 and Phase 2 (stages 1 & 2) studies.
OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. CD19 is a membrane glycoprotein present on the surface of all stages of B lymphocyte development, and is also expressed on most B-cell mature lymphoma cells and leukemia cells. CD22 is a glycoprotein expressed on B-lineage lymphoid precursors, including precursor B acute lymphoblastic leukemia, and often is co-expressed with CD19 on mature B-cell malignancies.
OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.
In an earlier Phase 1 clinical trial, twenty-five patients with mature or precursor B-cell lymphoid malignancies expressing CD19 and/or CD22 were enrolled. When the study allowed for an increase in the dose level (60 mg/kg) in the final 9 patients, durable objective responses occurred in 2 patients; one patient continues to be in complete remission after being administered 2 cycles of OXS-1550. For further information about the earlier Phase 1 clinical trial, see Bachanova, V., et. al., Clin Cancer Res; 21(6) March 15, 2015.
About Oxis Biotech, Inc.: Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-2175 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
Forward-Looking Statements: Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Oxis Biotech Inc., a wholly owned subsidiary of Oxis International Inc. [OTC: OXIS and Euronext Paris: OXI.PA] announced today that inventors of OXS-1550 received a Notice of Allowance from the United States Patent and Trademark Office (USPTO). Oxis holds worldwide exclusive rights to develop and commercialize OXS-1550, a novel therapy for the treatment of various human cancers.
"We are pleased the USPTO has agreed that OXS-1550 is a patentable therapeutic composition. This is a significant milestone for Oxis and will attribute meaningful value to our existing IP portfolio," said Anthony J. Cataldo, Chairman and Chief Executive Officer of Oxis Biotech.
Dr. Daniel Vallera, the inventor of OXS-1550 and Director of the Section on Molecular Cancer Therapeutics at the University of Minnesota Masonic Cancer Center, said he believes OXS-1550 will play an important role in the treatment of cancer. The drug is designed to identify certain cancer cells and kill them, without damaging healthy cells.
"We believe OXS-1550 to be a powerful alternative to existing chemotherapies, since many patients fail chemotherapy or reach the toxic limits of their therapy," Vallera said.
The patent decision comes as OXS-1550 is being evaluated in a new Phase 1/Phase 2 clinical trial. The objective of the Phase 1 study is to identify the Maximum Tolerated Dose (MTD), and the optimized dose and regimen to be used in the Phase 2 study.
Enrollment of patients into the Phase 2 study will begin after the Phase 1 study is completed. The Phase 2 study is a two-stage, two-ARM design. Patients from the Phase 1 study plus an additional 9 patients will be enrolled in stage 1 of the Phase 2 study. If one patient enrolled in the Phase 2, stage 1 part of the study has a positive response, then an additional 8 patients will be enrolled in the Phase 2 stage of the study. At a maximum, up to 29 patients will be enrolled across both the Phase 1 and Phase 2 (stages 1 & 2) studies.
OXS-1550 is a bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. CD19 is a membrane glycoprotein present on the surface of all stages of B lymphocyte development, and is also expressed on most B-cell mature lymphoma cells and leukemia cells. CD22 is a glycoprotein expressed on B-lineage lymphoid precursors, including precursor B acute lymphoblastic leukemia, and often is co-expressed with CD19 on mature B-cell malignancies.
OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-1550 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia.
In an earlier Phase 1 clinical trial, twenty-five patients with mature or precursor B-cell lymphoid malignancies expressing CD19 and/or CD22 were enrolled. When the study allowed for an increase in the dose level (60 mg/kg) in the final 9 patients, durable objective responses occurred in 2 patients; one patient continues to be in complete remission after being administered 2 cycles of OXS-1550. For further information about the earlier Phase 1 clinical trial, see Bachanova, V., et. al., Clin Cancer Res; 21(6) March 15, 2015.
About Oxis Biotech, Inc.: Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-2175 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
Forward-Looking Statements: Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
TAMPA, FL / ACCESSWIRE / February 21, 2017 / Oxis International, Inc. (OXIS) (OXIS.PA) parent company of Oxis Biotech, focused on the development and commercialization of immunotherapy for the treatment of cancer, announced today it received notification from the U.S. Patent and Trademark Office a patent will be issued on February 28, 2017 for its drug candidate OXIS-4235 for the treatment of myeloma.
The patent clears the way for Oxis Biotech to begin the process of pursuing clinical trials for the new drug.
The drug is a P62-ZZ chemical inhibitor intended for use as a treatment for multiple myeloma. According to the American Cancer Society, more than 30,000 people are expected to be diagnosed with the disease this year and more than 12,000 are expected to die from it.
Dr. Sean Xie of Pittsburgh, Pa., developed the drug. The drug is intended to stop the growth of multiple myeloma cells without harming healthy cells. In addition to shrinking the tumors, the dual purpose drug is also intended to increase bone density, a second benefit of the technology.
Oxis Biotech, through its licensing agreement with Dr. Xie, holds the exclusive worldwide rights to commercialize this technology.
"Bone density shrinkage is one of the biggest problems of multiple myeloma. Bones wither away. This dual action drug is extremely promising," said Oxis CEO Anthony Cataldo. "We have always had great confidence in Dr. Xie's work related to multiple myeloma. The issuance of this patent points out the unique and novel technology Dr. Xie has developed. We are incredibly happy to add it to our pipeline."
The USPTO indicated it will issue Patent No. 9,580,382 for the technology on February 28, 2017.
About Oxis Biotech, Inc.: Oxis Biotech is an immuno-oncology focused company developing innovative drugs focused on the treatment of cancer and other unmet medical needs. OXIS' lead drug candidate, OXS-1550 (DT2219ARL) is a novel bispecific scFv recombinant fusion protein-drug conjugate composed of the variable regions of the heavy and light chains of anti-CD19 and anti-CD22 antibodies and a modified form of diphtheria toxin as its cytotoxic drug payload. OXS-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors. When OXS-2175 binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug's cytotoxic payload. OXS-1550 has demonstrated success in early human clinical trials in patients with relapsed/refractory B-cell lymphoma or leukemia. OXS-4235 is a small molecule therapeutic candidate targeting the treatment of multiple myeloma and associated osteolytic lesions. In in vitro and in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma cells, and decrease osteolytic lesions in bone. OXIS' lead drug candidate, OXS-2175, is a small molecule therapeutic candidate targeting the treatment of triple-negative breast cancer (TNBC). In in vitro and in vivo models of TNBC, OXS-2175 demonstrated the ability to inhibit metastasis.
Forward-Looking Statements: Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Oxis International, Inc. (OXIS) (OXIS.PA) parent company of Oxis Biotech
Only 1 patient was allowed the optimal high dose twice.
That's when that lady was cured from cancer :)
The patents are solid.
They have one of the best patent attorneys in the game :)
Worldwide Exclusive rights :)
That is why everyone is invested here huge value including you :)